The driving‐related attitudes, beliefs and behaviours of cannabis users in the Australian Capital Territory following decriminalisation

Drug and Alcohol Review, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 7, 2025

Abstract Introduction In January 2020, the government of Australian Capital Territory (ACT) decriminalised possession and cultivation cannabis for personal use. This study explored driving‐related attitudes, beliefs behaviours ACT residents who are legally cultivating consuming cannabis. Methods A two‐part cross‐sectional was conducted. Part‐1: Cannabis users residing in were invited to complete an online survey. Part‐2: Survey respondents reported ‘currently growing’ submit a sample their home‐grown phytocannabinoid analysis. Data from Parts 1 2 used estimate participants' usual Δ 9 ‐tetrahydrocannabinol (THC) intakes. Results N = 385 completed all or part survey 52 submitted samples Most participants ( 224/330; 67.9%) waiting ≥7 h following use before driving. However, 21.5% 71/330) ≤3 h. These individuals had highest THC intakes (where known). Further analyses revealed that expressed less concern about roadside drug testing effects non‐medicinal medicinal on driving, more frequently, larger amounts, exclusively purposes likely report shorter ‘wait times’. Discussion Conclusion small proportion appear be driving shortly (i.e., h) after considerable quantities THC. behaviour puts them at risk while impaired incurring legal sanctions. Interventions alerting these possible risks are, therefore, warranted.

Language: Английский

---

A Systematic Review of Cannabis and Anxiety: Chicken or Egg?

Current Addiction Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: April 11, 2025

Language: Английский

---

How cannabis consumption relates to negative affect and expectancies: A cross-sectional survey of an international Spanish-speaking sample

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Background Research suggests that individuals who use cannabis often have more positive expectations about its effects compared to those do not. Cannabis is also associated with increased negative affect, but the impact of these affective symptoms on relationship between expectation and frequency has not been fully explored. Preliminary descriptive outcomes for this study looked at differences in affect expectancies based status, location residence, gender. The study's primary aim investigates if moderates use. Methods Participants (N = 421) were recruited nationally internationally through online platforms community, an average age 30 years. Of sample, 49.4% female, 53.2% US-residents, 47.7% currently using cannabis. Self-report questionnaires assessed last week, effects, Results Those had significantly higher lower U.S. residents reported than international residents. Regression models showed predicted use, decreased A significant interaction was found amplifying association frequency. Conclusions These results support role patterns extend literature suggest strengthen findings highlight importance addressing both states a variety populations when understanding patterns.

Language: Английский

---

Cannabis use is associated with less peripheral inflammation but similar insulin sensitivity as non-use in healthy adults

The American Journal of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

---

Phytocannabinoids as Chemotherapy Adjuncts – a User Guide

Published: Aug. 21, 2024

Simple Summary (148 words) There is increasing evidence, that cannabinoids may play an important and dual role in tumour therapy. On one hand, they are cytotoxic against cancer cells with a low toxicity normal, healthy tissues, on the other, reduce typical side effects of chemotherapy. Publications main motive for use cannabis (cannabinoids) by patients show patients' expectations exceed scientific facts. This article briefly describes results combinations standard antineoplastic drugs tumours Although observations still limited to animal studies very few experiences patients, preliminary data suggest adjuvant improve survival glioblastoma perhaps other tumours. Benefits have also been reported about chemotherapy-induced nausea vomiting, peripheral neuropathic pain, loss appetite anxiety. promising, much more research necessary. Abstract (192 Cancer, leading causes death worldwide, rise. The high conventional chemotherapy, often applied as drug cocktails, resistance development limits anti-neoplastic reduces quality life. With easier access, growing number using alleviation their symptoms, hope improving survival. narrative summarizes observed phytocannabinoids chemotherapeutic agents models patients. Preliminary combined exert increased anti-cancer actions, Respective scarce concern small numbers glioblastoma, pancreatic carcinoma. Further benefits (dronabinol), pain anxiety (cannabidiol). In addition, phytocannabinoids, particular cannabidiol, protection organs such heart, lung or kidney toxicity. needed determine whether positive outweigh eventual risks.

Language: Английский

---

Cannabis for medicine and food: A benefit vs risk critical appraisal

South African Journal of Botany, Journal Year: 2024, Volume and Issue: 175, P. 15 - 31

Published: Oct. 11, 2024

Language: Английский

---

Phytocannabinoids as Chemotherapy Adjuncts—A Review for Users

Onco, Journal Year: 2024, Volume and Issue: 4(4), P. 287 - 321

Published: Oct. 11, 2024

Cancer, one of the leading causes death worldwide, is on rise. The high toxicity conventional chemotherapy, often applied as drug cocktails, and development resistance limit use antineoplastic drugs reduce quality life. With easier access, a growing number patients are using cannabis (cannabinoids) for alleviation their symptoms, in hope improving survival. This article summarizes results observed with combinations phytocannabinoids standard chemotherapeutic agents animal tumour models patients. It limited to approved phytocannabinoids. Preliminary preclinical data suggest that combined cannabinoids exert enhanced anti-cancer effects, improve Corresponding experiences still very only concern few glioblastoma pancreatic cancer. Benefits containing have also been reported chemotherapy-induced nausea vomiting, loss appetite (dronabinol), peripheral neuropathic pain anxiety (cannabidiol). In addition, phytocannabinoids, particularly cannabidiol, may play role protecting organs such heart, lungs or kidneys from chemotherapy-related toxicity. Although promising, more research needed ensure whether benefits adjuvant outweigh potential risks.

Language: Английский

---

Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin

Cannabis and Cannabinoid Research, Journal Year: 2024, Volume and Issue: unknown

Published: June 17, 2024

Introduction: In Colorado, both cannabis and psilocybin are legal becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of co-use motives that may perpetuate these coping, boredom).

Language: Английский

---

The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(10), P. 1335 - 1335

Published: Oct. 6, 2024

The public is increasingly reporting using cannabis for anxiety relief. Both use and the endocannabinoid system have been connected with relief/anxiolytic properties, but these relationships are complex, underlying mechanisms them unclear.

Language: Английский

---